Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 14/20 | 0.51 |
| ▸ | MEN1 | O00255 | 10/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.51 |
| ▸ | GFER | P55789 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MARS1 | P56192 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771011 | 0.84 | GAA (0.54) | GAAMEN1KMT2AGFERHSD17B10 | |
| SCHEMBL771000 | 0.84 | CCR3 (0.49) | MEN1KMT2AALDH1A1HTTKDM4E | |
| SCHEMBL10138743 | 0.82 | GAA (0.49) | GAAMEN1KMT2AGFERHSD17B10 | |
| SCHEMBL10138138 | 0.80 | HTR3A (0.51) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL770002 | 0.79 | PRMT5 (0.41) | GAAALDH1A1MAPTTP53LMNA | |
| SCHEMBL770274 | 0.78 | KEAP1 (0.52) | MEN1KMT2AHPGD | |
| SCHEMBL770297 | 0.76 | GAA (0.52) | GAAMEN1KMT2AGFERHSD17B10 | |
| SCHEMBL770901 | 0.75 | LMNA (0.44) | KMT2AHTTTDP1LMNA | |
| SCHEMBL770378 | 0.74 | EPHX2 (0.56) | MEN1KMT2AHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL771039 | 0.74 | EPHX1 (0.42) | TDP1LMNAPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2439202-B1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | SALVAT LAB SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | GAA 751/4885MEN1 827/4885KMT2A 3868/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | GAA 746/4885MEN1 823/4885KMT2A 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.